Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 85

1.

Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.

Antonarakis ES, Heath EI, Walczak JR, Nelson WG, Fedor H, De Marzo AM, Zahurak ML, Piantadosi S, Dannenberg AJ, Gurganus RT, Baker SD, Parnes HL, DeWeese TL, Partin AW, Carducci MA.

J Clin Oncol. 2009 Oct 20;27(30):4986-93. doi: 10.1200/JCO.2009.21.9410. Epub 2009 Aug 31.

PMID:
19720908
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.

Pruthi RS, Derksen JE, Moore D, Carson CC, Grigson G, Watkins C, Wallen E.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2172-7.

PMID:
16609031
[PubMed - indexed for MEDLINE]
Free Article
3.

A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer.

Sooriakumaran P, Coley HM, Fox SB, Macanas-Pirard P, Lovell DP, Henderson A, Eden CG, Miller PD, Langley SE, Laing RW.

Anticancer Res. 2009 May;29(5):1483-8.

PMID:
19443354
[PubMed - indexed for MEDLINE]
Free Article
4.
5.

Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.

Narayanan BA, Reddy BS, Bosland MC, Nargi D, Horton L, Randolph C, Narayanan NK.

Clin Cancer Res. 2007 Oct 1;13(19):5965-73.

PMID:
17908994
[PubMed - indexed for MEDLINE]
Free Article
6.

Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.

Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, Fu P, Mukhtar H.

Cancer Res. 2004 May 1;64(9):3334-43.

PMID:
15126378
[PubMed - indexed for MEDLINE]
Free Article
7.

Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.

Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW.

J Clin Oncol. 2006 Jun 20;24(18):2723-8.

PMID:
16782912
[PubMed - indexed for MEDLINE]
Free Article
8.

Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.

Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Levin B, Hawk ET, Cohen DS, Ayers GD, Stephens LC; Familial Adenomatous Polyposis Study Group.

Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):920-7.

PMID:
15184247
[PubMed - indexed for MEDLINE]
Free Article
9.

A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancer.

Sooriakumaran P, Macanas-Pirard P, Bucca G, Henderson A, Langley SE, Laing RW, Smith CP, Laing EE, Coley HM.

Cancer Genomics Proteomics. 2009 Mar-Apr;6(2):93-9.

PMID:
19451093
[PubMed - indexed for MEDLINE]
Free Article
10.

Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.

Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM.

J Clin Oncol. 2011 Nov 10;29(32):4320-6. doi: 10.1200/JCO.2011.35.5214. Epub 2011 Oct 11.

PMID:
21990410
[PubMed - indexed for MEDLINE]
Free Article
11.

Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study.

Ganswindt U, Budach W, Jendrossek V, Becker G, Bamberg M, Belka C.

Radiat Oncol. 2006 Apr 10;1:9.

PMID:
16722607
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer.

Martin LA, Davies GL, Weigel MT, Betambeau N, Hills MJ, Salter J, Walsh G, A'Hern R, Dowsett M.

Breast Cancer Res Treat. 2010 Oct;123(3):829-36. doi: 10.1007/s10549-010-1100-z. Epub 2010 Aug 10.

PMID:
20697803
[PubMed - indexed for MEDLINE]
13.

Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.

Eastham JA, Kelly WK, Grossfeld GD, Small EJ; Cancer and Leukemia Group B.

Urology. 2003 Dec 29;62 Suppl 1:55-62.

PMID:
14747042
[PubMed - indexed for MEDLINE]
14.

Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.

Clark PE, Peereboom DM, Dreicer R, Levin HS, Clark SB, Klein EA.

Urology. 2001 Feb;57(2):281-5.

PMID:
11182337
[PubMed - indexed for MEDLINE]
15.

The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.

Gasparini G, Meo S, Comella G, Stani SC, Mariani L, Gamucci T, Avallone A, Lo Vullo S, Mansueto G, Bonginelli P, Gattuso D, Gion M.

Cancer J. 2005 May-Jun;11(3):209-16.

PMID:
16053664
[PubMed - indexed for MEDLINE]
16.

The design of a randomized, placebo-controlled trial of celecoxib in preprostatectomy men with clinically localized adenocarcinoma of the prostate.

Heath EI, DeWeese TL, Partin AW, De Marzo AM, Groopman JD, Nelson WG, Piantadosi SA, Lieberman R, Carducci MA.

Clin Prostate Cancer. 2002 Dec;1(3):182-7. No abstract available.

PMID:
15046694
[PubMed - indexed for MEDLINE]
17.

Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities.

Nguyen MM, Ahmann FR, Nagle RB, Hsu CH, Tangrea JA, Parnes HL, Sokoloff MH, Gretzer MB, Chow HH.

Cancer Prev Res (Phila). 2012 Feb;5(2):290-8. doi: 10.1158/1940-6207.CAPR-11-0306. Epub 2011 Nov 1.

PMID:
22044694
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice.

Zheng X, Cui XX, Avila GE, Huang MT, Liu Y, Patel J, Kong AN, Paulino R, Shih WJ, Lin Y, Rabson AB, Reddy BS, Conney AH.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5480-7.

PMID:
17875778
[PubMed - indexed for MEDLINE]
Free Article
19.

Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.

Daniels S, Robbins J, West CR, Nemeth MA.

Clin Ther. 2009 Jun;31(6):1192-208. doi: 10.1016/j.clinthera.2009.06.003.

PMID:
19695387
[PubMed - indexed for MEDLINE]
20.

Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.

Marberger M, Freedland SJ, Andriole GL, Emberton M, Pettaway C, Montorsi F, Teloken C, Rittmaster RS, Somerville MC, Castro R.

BJU Int. 2012 Apr;109(8):1162-9. doi: 10.1111/j.1464-410X.2011.10373.x. Epub 2011 Jun 23.

PMID:
21699645
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk